reports
ACV Auctions Inc: 1 director
A director at ACV Auctions Inc sold/sold after exercising options 100,000 shares at 17.170USD and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors...
Coinbase Global Inc: 3 directors
A director at Coinbase Global Inc sold 23,075 shares at 238.264USD and the significance rating of the trade was 99/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...
Natera Inc: 2 directors
Two Directors at Natera Inc sold/sold after exercising options 86,816 shares at between 90.821USD and 93.133USD. The significance rating of the trade was 80/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the comp...
EQS-News: Hypoport SE: Marktanteilsgewinne und Marktwachstum lassen Ge...
EQS-News: Hypoport SE / Schlagwort(e): Marktbericht Hypoport SE: Marktanteilsgewinne und Marktwachstum lassen Geschäftsvolumen in Q1 deutlich steigen 18.04.2024 / 07:15 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Operative Kennzahlen Q1/24 Hypoport SE: Marktanteilsgewinne und Marktwachstum lassen Geschäftsvolumen in Q1 deutlich steigen Europace Transaktionsvolumen steigt in Q1/24 erstmals seit Einbruch des Immobilienfinanzierungsmarktes wieder prozentual zweistellig gegenüber Vorjahresquartal Volumen von Genossenschaftsba...
EQS-News: Hypoport SE: business volume rises sharply in Q1 thanks to m...
EQS-News: Hypoport SE / Key word(s): Market Report Hypoport SE: business volume rises sharply in Q1 thanks to market share gains and market growth 18.04.2024 / 07:15 CET/CEST The issuer is solely responsible for the content of this announcement. Operational key figures for Q1 2024 Hypoport SE: business volume rises sharply in Q1 thanks to market share gains and market growth Q1 2024 sees the first double-digit year-on-year increase in the Europace transaction volume since the slump in the mortgage finance market Volume from cooperative banks and savings banks ju...
Sartorius Stedim Biotech publishes unaudited first quarter results for...
Sartorius Stedim Biotech SA / Key word(s): Quarter Results Sartorius Stedim Biotech publishes unaudited first quarter results for 2024 18-Apr-2024 / 07:02 CET/CEST Aubagne, France | April 18, 2024 Sartorius Stedim Biotech publishes unaudited first quarter results for 2024 Sales revenue of 667 million euros, in constant currencies1 - 9.4 percent organically1and - 6.7 percent including acquisitions2(reported: - 8.2 percent) Order intake up 13.9 percent to 676 million euros (reported: 12.5 percent) with significant growth in recurring business, while demand from China remains we...
EQS-News: Sartorius: Ergebnisse des 1. Quartals im Rahmen der Erwartun...
EQS-News: SARTORIUS AG / Schlagwort(e): Quartalsergebnis Sartorius: Ergebnisse des 1. Quartals im Rahmen der Erwartungen; Wiederholgeschäft mit deutlichem Auftragswachstum; Nachfrage aus China weiter schwach; Ausblick für Gesamtjahr bestätigt (News mit Zusatzmaterial) 18.04.2024 / 07:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Göttingen, 18. April 2024 Sartorius: Ergebnisse des 1. Quartals im Rahmen der Erwartungen; Wiederholgeschäft mit deutlichem Auftragswachstum; Nachfrage aus China weiter schwach; Ausblick für Gesamtjahr ...
EQS-News: Sartorius: First quarter results in line with expectations; ...
EQS-News: SARTORIUS AG / Key word(s): Quarter Results Sartorius: First quarter results in line with expectations; recurring business with significant order growth; demand from China remains weak; outlook for full year confirmed (news with additional features) 18.04.2024 / 07:00 CET/CEST The issuer is solely responsible for the content of this announcement. Göttingen, April 18, 2024 Sartorius: First quarter results in line with expectations; recurring business with significant order growth; demand from China remains weak; outlook for full year confirmed Inventory reduc...
Biophytis announces new Scientific Advisory Board for its phase 2 OBA ...
Biophytis / Key word(s): Miscellaneous Biophytis announces new Scientific Advisory Board for its phase 2 OBA clinical study in obesity 18-Apr-2024 / 07:02 CET/CEST Biophytis announces new Scientific Advisory Board for its phase 2 OBA clinical study in obesity IND to be filed with the FDA in the coming weeks Paris (France) and Cambridge (Massachusetts, USA), April 18, 2024 – 07:00am CET – Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics for age-relat...
Biophytis annonce la création d'un Conseil Scientifique pour son étude...
Biophytis / Mot-clé(s) : Autres Biophytis annonce la création d'un Conseil Scientifique pour son étude clinique de phase 2 OBA dans l'obésité 18-Avr-2024 / 07:02 CET/CEST Biophytis annonce la création d'un Conseil Scientifique pour son étude clinique de phase 2 OBA dans l'obésité Dépôt d’IND auprès de la FDA dans les prochaines semaines Paris, France, Cambridge (Massachusetts, États-Unis), 18 avril 2024 – 7h00 – Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), («Biophytis» ou la «Société»), une société de biotechnologie au stade clinique spécialisée dans le dév...
Journée des marchés des capitaux: Mobimo donne un aperçu approfondi de...
Mobimo Holding AG / Mot-clé(s) : Conférence/Immeubles Journée des marchés des capitaux: Mobimo donne un aperçu approfondi de ses projets clés et du pipeline de projets 18.04.2024 / 07:00 CET/CEST Communiqué de presse Journée des marchés des capitaux: Mobimo donne un aperçu approfondi de ses projets clés et du pipeline de projets Lucerne, le 18 avril 2024 – Mobimo accueille aujourd’hui à Zurich les investisseurs, les analystes, les représentants des bailleurs de fonds ainsi que les journalistes à l’occasion de la Journée des marchés des capitaux. A cette occasion, les six...
Kapitalmarkttag: Mobimo gibt vertieften Einblick in Schlüsselprojekte ...
Mobimo Holding AG / Schlagwort(e): Konferenz/Immobilien Kapitalmarkttag: Mobimo gibt vertieften Einblick in Schlüsselprojekte und Pipeline 18.04.2024 / 07:00 CET/CEST Medienmitteilung Kapitalmarkttag: Mobimo gibt vertieften Einblick in Schlüsselprojekte und Pipeline Luzern, 18. April 2024 – Mobimo begrüsst heute Investoren, Analysten, Vertreter von Kreditgebern sowie Medienschaffende in Zürich zum Kapitalmarkttag. Das sechsköpfige Management gibt dabei einen vertieften Einblick in wichtige Projekte sowie in die Projektpipeline. Einleitend rekapituliert Daniel Ducrey, CE...
Capital Markets Day: Mobimo offers deeper insights into key projects a...
Mobimo Holding AG / Key word(s): Conference/Real Estate Capital Markets Day: Mobimo offers deeper insights into key projects and pipeline 18.04.2024 / 07:00 CET/CEST Press release Capital Markets Day: Mobimo offers deeper insights into key projects and pipeline Lucerne, 18 April 2024 – Mobimo is welcoming investors, analysts, representatives of lenders and members of the media to its Capital Markets Day in Zurich today. The company’s six-member Executive Board will provide deeper insights into key projects and the project pipeline. To begin the event, Daniel Ducrey, C...
Sartorius Stedim Biotech publie ses résultats non audités pour le prem...
Sartorius Stedim Biotech SA / Mot-clé(s) : Résultat trimestriel Sartorius Stedim Biotech publie ses résultats non audités pour le premier trimestre 2024 18-Avr-2024 / 07:02 CET/CEST Aubagne, France | 18 avril 2024 Sartorius Stedim Biotech publie ses résultats non audités pour le premier trimestre 2024 Chiffre d’affaires à 667 millions d’euros, soit une baisse organique de 9,4 % à taux de change constant1 et une baisse de 6,7 % à taux de change constant en tenant compte des acquisitions2(baisse déclarée : - 8,2 %) Augmentation des prises de commandes de 13,9 % à 676 millions d...
Surgery Partners, Inc. Announces First Quarter 2024 Earnings Release D...
Surgery Partners, Inc. Announces First Quarter 2024 Earnings Release Date and Conference Call Details BRENTWOOD, Tenn., April 18, 2024 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, announced the Company will release its first quarter 2024 results before the market opens on Tuesday, May 7, 2024, to be followed by a conference call at 8:30 a.m. (Eastern Time). You can join the call as follows: Dial in number for live access: 1-877-451-6152 (domestic), 1-201-389-0879 (international)...
- Pierre FerraguÊ
Ensari Deri Gida Sanayi Ve Ticaret A S: 1 director
A director at Ensari Deri Gida Sanayi Ve Ticaret A S sold 4,400,000 shares at 30.780TRY and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over ...
Salesforce Inc: 4 directors
A director at Salesforce Inc sold after exercising options 5,864 shares at 274.773USD and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over th...
Cencora Inc: 2 directors
A director at Cencora Inc sold/sold after exercising options 57,564 shares at 235.090USD and the significance rating of the trade was 83/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over...
Belysse Group N.V.: 1 director
A director at Belysse Group N.V. bought 35,786 shares at 0.920EUR and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.